<DOC>
	<DOCNO>NCT00822744</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy 3 fixed dos SSR411298 ( 10 , 50 200 mg daily ) compare placebo , elderly patient Major Depressive Disorder ( MDD ) , base 17-item Hamilton Depression Rating Scale . Secondary objective : - To evaluate tolerability safety 8-week treatment SSR411298 versus placebo elderly patient MDD . - To evaluate effect SSR411298 disability , anxiety , cognitive function , sleep , pain somatic symptom relate depression , bone marker . - To assess SSR411298 plasma concentration . - To assess plasma endocannabinoid concentration .</brief_summary>
	<brief_title>An Eight-week Study SSR411298 Treatment Major Depressive Disorder Elderly Patients</brief_title>
	<detailed_description>The study period participant approximately 10 week include screen 1 week , 8-week treatment 1-week follow-up .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Elderly patient recurrent Major Depressive Disorder Duration current depressive episode great 2 year ; Mild depression measure standard clinical research scale ; Cognitive disturbance ; Significant suicide risk ; Other psychiatric condition would obscure result study ; History failure respond antidepressant treatment . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Episode</keyword>
	<keyword>Antidepressant</keyword>
</DOC>